Alpine's Electric Sports Car Will Have 'A Lot' Of Power
A390
SUV. But that's merely one of many EVs that the French automaker has planned over the next few years. Alpine will release a new electric sports car to succeed the A110, and the company promises it will be plenty powerful.
In an interview with
Auto Express
, CEO Philippe Krief and Renault Group head Luca de Meo revealed more details about the upcoming electric sports car. The duo noted that it has a targeted weight of around 3,200 pounds (1,450 kilograms) and is expected to have a range of approximately 350 miles on the WLTP cycle.
Alpine A110 E-Ternity EV Concept
Most importantly, this new sports car will be powerful. When asked how much power the new EV sports car could produce, Krief responded with: "A lot! There will be enough power, I can guarantee."
The outgoing
A110
produces up to 296 horsepower at its most powerful, but we expect the EV to be even punchier still. Alpine touts two configurations: Dual- and tri-motor setups, with the dual-motor configuration sending power exclusively to the rear wheels, and the tri-motor setup offering all-wheel drive.
The sports car will be the first vehicle in the lineup to use the automaker's 800-volt Alpine Performance Platform (APP), which debuts at the Paris Motor Show next year. The APP architecture will go on to underpin "three or four models," de Meo notes, with electric motors mounted in the wheels themselves. The wheel-mounted motors, de Meo says, will help lower the car's center of gravity, and give the car mid-engine proportions.
As mentioned, Alpine is aiming for a curb weight of around 3,200 pounds for its electric sports car—or just about as much as a gas Porsche Cayman. That will be slightly heavier than the A110, which tips the scales at just around 2,400 pounds, but relatively light for a BEV.
We don't know when Alpine plans to debut its new electric sports car, but if we're lucky, we could see the coupe as early as next year alongside the brand's new APP architecture in Paris. As for whether or not this new sports car will come to the US—we're holding out hope.
The Latest From Alpine
Alpine Wants to Take on Ferrari With a 1,000-HP Hybrid Hypercar
Alpine's First Electric Sports Car Has Mid-Engine Proportions
Get the best news, reviews, columns, and more delivered straight to your inbox, daily.
back
Sign up
For more information, read our
Privacy Policy
and
Terms of Use
.
Source:
Auto Express
Share this Story
X
Got a tip for us? Email:
tips@motor1.com
Join the conversation
(
)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
4 hours ago
- UPI
Sales at Kering-owned luxury brand Gucci drop 25%
On Tuesday, France-based Kering, the owner of well-known brands such as Gucci and Balenciaga, reported worse second-quarter financial returns than what was expected. It pointed to "uncertain" global factors. Gucci sales dropped 15% year-on-year to around $4.27 billion versus its projected $4.5 billion. Over the quarter, Gucci sales also went down 25%. File Photo (2021) by John Angelillo/UPI | License Photo July 29 (UPI) -- France-based Kering, the owner of Gucci, on Tuesday reported lower second-quarter financial returns than what was expected, pointing to "uncertain" global factors. Gucci sales dropped 15% year-on-year to about $4.27 billion versus its projected $4.5 billion. Over the quarter, sales at the Italian luxury brand also went down 25%. "Though the numbers we are reporting remain well below our potential, we are certain that our comprehensive efforts of the past two years have set healthy foundations for the next stages in Kering's development," company Chairman and CEO François-Henri Pinault said in a statement acknowledging the disappointing numbers. Stock value in Kering fell nearly a quarter in the past year alone. Kering, which owns other brands such as Bottega Veneta and Saint Laurent, noted that sales were weaker across the board primarily in Japan and the Asia-Pacific region. Saint Laurent, the second-largest Kering-owned brand, also saw sales down by 10% in the quarter. On Tuesday, Kering's CFO Armelle Poulou told the Financial Times that sales in Gucci improved among North American consumers. She added its Bottega eyewear division had grown by a single digit. The company says in an economic and geopolitical environment that "remains uncertain," it continues to "deploy its strategy with the aim of achieving a profitable long-term growth trajectory." In an email, Third Bridge analyst Yanmei Tang told CNBC that Kering is facing a "tough reality as its two main luxury markets, China and the United States, are under strain." The French luxury group announced in 2021 that it banned the use of animal fur across all Kering-owned companies.
Yahoo
5 hours ago
- Yahoo
Gucci owner Kering posts 46% profit slump before new CEO arrives
French luxury group Kering reported Tuesday a 46 percent plunge in net profit during the first half, with sales slumping again at its flagship Gucci brand, as the group awaits a new CEO to try to regain its footing. Group net profit fell to 474 million euros ($547 million) in the first half from 878 million in the same period last year, on sales that were down 16 percent at 7.6 billion euros. Kering announced in June that it had poached Luca de Meo, then the head of French automaker Renault, to become chief executive and help turn around the company alongside Francois-Henri Pinault, who will remain board chairman. Pinault's family controls the holding company that is the largest shareholder in Kering, whose crosstown rival LVMH reported last week a 22 percent drop in first-half profit. Luxury groups worldwide have been hit hard by slowing Chinese appetite for luxury goods and by US President Donald Trump's barrage of tariffs since returning to office this year, which could crimp demand in a North American market that represents a fourth of Kering's sales. "Though the numbers we are reporting remain well below our potential, we are certain that our comprehensive efforts of the past two years have set healthy foundations for the next stages in Kering's development," Pinault said in a statement. Gucci remains the prize in Kering's stable of brands, generating 44 percent of its sales and roughly two-thirds of its operating profit. But it has struggled to turn things around at the Italian fashion house famous for its handbags, and in March it wooed the Georgian designer Demna to take over as artistic director. Gucci's sales dropped 26 percent in the first half to 3.03 billion euros, for an operating profit of 486 million euros -- down 52 percent. - 'Vigilance' - But investors may have to wait for a recovery plan from De Meo, who has yet to take up his post. "The change in group management is positive, but earnings will remain under pressure in the short term," analysts at HSBC said in a note before the earnings release. "Luca de Meo will not take up his post until September 15, and it's unlikely that he will present his strategic plan before the publication of full-year results, expected in February 2026," they said. Kering's two other top brands are also facing headwinds, with Yves Saint Laurent sales falling 11 percent in the first half to 1.29 billion euros, and Bottega Veneta sales up just one percent at 846 million euros. Kering must also contend with a debt load that stood at 9.5 billion euros at the end of June, the result of acquisitions and investments in recent years. It bought a 30 percent stake in Valentino, took over the beauty brand Creed, and opened stores on key but pricey sites in cities including Paris and Milan. "Selling this real estate (below the purchase cost) is a bitter but necessary solution," analysts at Bernstein wrote ahead of the earnings statement. Kering said it was "stepping up the initiatives needed to support the development and growth of its houses, while implementing with determination the efforts required to increase its efficiency". "These actions imply particular vigilance with regards to financial discipline," it added. kap/ak/js/ Sign in to access your portfolio
Yahoo
11 hours ago
- Yahoo
Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk
Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeeds Lars Fruergaard Jørgensen, who will step down as president and chief executive officer on the same date. The company also announced other executive-level changes, effective 7 August. Mike Doustdar, currently Novo Nordisk's executive vice president of International Operations, has a strong track record of creating value and driving growth. Under his leadership over the past decade, Novo Nordisk's International Operations have more than doubled sales to approximately DKK 112 billion in 2024. The business includes all of Novo Nordisk's affiliates outside of the US and employs nearly 20,000 people. Novo Nordisk Chair, Helge Lund, said: 'Mike is an exceptional leader and has the unanimous support of the Board. We are confident that he is the best person to lead Novo Nordisk through its next growth phase. Mike has consistently demonstrated the ability to drive growth through strong commercial execution and building high-performing teams. This is an important moment for Novo Nordisk. The market is developing rapidly, and the company needs to address recent market challenges with speed and ambition. I believe Novo Nordisk will build on its strengths as a global leader in obesity and diabetes, and Mike has a clear vision of how to unlock the full potential of the opportunities ahead.' Mike Doustdar has been appointed as the result of a comprehensive process that included external and internal candidates. The Novo Nordisk Foundation fully endorses Novo Nordisk Board's decision to appoint Maziar Mike Doustdar as president and chief executive officer. Mike Doustdar said: 'It's an enormous privilege to lead this company at a time of tremendous opportunity and change. I come to this role with a sense of urgency, a laser focus on high performance, and a fierce determination for Novo Nordisk to aim higher than it's ever done, and to deliver to many more patients the innovation they need. From my decades in leadership roles across Novo Nordisk, I know the extraordinary talent and commitment of our people and the excellence of our science. This has enabled us to achieve great things in the past and will ensure we continue to do so in the future.' Novo Nordisk Chair, Helge Lund, added: 'Under Lars's leadership, Novo Nordisk has undergone a profound period of growth and now reaches millions more patients with life-changing medicines. On behalf of Novo Nordisk's Board of Directors and our employees, I want to thank Lars for 34 years of unstinting commitment to the company and wish him all the best in his future endeavours.' Other organisational changes effective 7 August: Research & Early Development and Development EVP areas will be merged into a combined R&D Nordisk has decided to merge the company's Research & Early Development with its Development area into a new, consolidated R&D unit, under the leadership of Martin Holst Lange, MD, PhD. Martin Holst Lange, currently executive vice president, Development, will be appointed chief scientific officer (CSO), effective 7 August. Martin Holst Lange will focus on seamlessly combining the two functions, quickly advancing the innovation of new therapies and ensuring the success of the early and late-stage pipelines, with a significant focus on the diabetes and obesity areas. In addition, Martin Holst Lange will work closely with Mike Doustdar to drive pipeline development and innovation from both within and outside of the company. Marcus Schindler, executive vice president, Research & Early Development and CSO, has decided to retire from the company. Novo Nordisk Chair, Helge Lund, said: 'We thank Marcus for his deep commitment to Novo Nordisk and its pursuit of scientific excellence. We wish him all the best for the future.' Marcus Schindler joined Novo Nordisk in January 2018 as senior vice president of External Innovation and Strategy and has been CSO since 2021. Marcus Schindler has played an integral role in leading the discovery of early scientific innovation. He will remain at Novo Nordisk for a short period to ensure a successful transition. Emil Kongshøj Larsen, currently senior vice president of the Europe and Canada region (EUCAN), will join Executive Management and succeed Mike Doustdar, assuming the responsibility of executive vice president, International Operations. Emil Larsen currently leads a region spanning 40 countries, accounting for about 20% of Novo Nordisk's global sales. He has previously led other significant business areas throughout Europe, Africa and the Middle East, as well as Commercial Affairs and Strategy in International Operations. With these changes, Executive Management will have the following members, effective 7 August: Maziar Mike Doustdar, president and CEO* Thilde Hummel Bøgebjerg, EVP, Quality, IT & Environmental Affairs Emil Kongshøj Larsen, EVP, International Operations Ludovic Helfgott, EVP, Product & Portfolio Strategy Karsten Munk Knudsen, EVP, chief financial officer* Martin Holst Lange, EVP, chief scientific officer, Research & Development David Moore, EVP, US Operations Tania Sabroe, EVP, People, Organisation and Corporate Affairs Henrik Wulff, EVP, CMC & Product Supply * Registered as an executive with the Danish Business Authority. About Maziar Mike DoustdarMike Doustdar became senior vice president of International Operations in 2013, a business that includes 80 affiliates - all of Novo Nordisk's commercial affiliates outside of the US. Novo Nordisk's International Operations had sales of approximately DKK 112 billion in 2024 and serve approximately 35 million patients. Prior to this role, Mike led Novo Nordisk's Southeast Asia and Oceania commercial area out of Malaysia, following on from his leadership of the Middle East business. Prior to this, he was general manager based in Turkey and held leadership roles in finance and IT. Mike Doustdar became executive vice president in 2015. He is a member of the Board of Directors of Orion Corporation. Conference CallNovo Nordisk will host a conference call for investors at 14.30 CEST on 29 July 2025, corresponding to 8.30 am EST. For more information on how to listen, please visit the investor section of There will be a conference call for media at 16.00 CEST, which corresponds to 10.00 am EST. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ Publication of inside information pursuant to Market Abuse Regulation, Article 17 Company announcement No 19 / 2025 Attachment CA250729-CEO-succession
